health careMarket Research Newsmedical devicesNews

Global Breast Cancer Drug Market Report 2019 Estimating $ 43.63 Billion Growth by 2026

The Breast Cancer Drug Market is likely to show substantial growth of percent across the industry over the 2019-2026 forecast period. The report includes an analysis and discussion of important industry trends, market size, estimates of market share. The study also offers market opportunities that are expected. The competitive landscape section of the report provides a clear insight into the market share analysis of key players in the industry. The report mentions the company profiles of all the key players and brands that dominate the Breast Cancer Drug market with movements such as product launches, joint ventures, mergers, and charges that in turn affect sales, import, export, and revenue. The report also mentions estimates of the CAGR value’s rise or fall over a given forecast period. Breast Cancer Drug Market Report also lists leading competitors and provides insights into the strategic sector Analysis of key factors affecting the industry.

Download Sample PDF Report:

Key Developments in the Market On 11 Mar 2019, F. Hoffmann-La Roche Ltd received accelerated approval for Tecentriq (atezolizumab ) in combination with Abraxane for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). On 28 Feb 2019, F. Hoffmann-La Roche Ltd received FDA approval for the Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) in combination with chemotherapy which is administered through subcutaneous route for the treatment of HER2-positive breast cancer. On 26 Apr 2019, Pfizer Inc. received positive CHMP of European Medicines Agency (EMA) opinion for Talzenna (talazoparib) for the treatment of patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally advanced (LA) or metastatic breast cancer (MBC) provided that patient previously treated with an anthracycline and/or a taxane medication.

Key Market Players: Global Breast Cancer Drug Market

Few of the major competitors currently working in the Breast Cancer Drug Market are

  • AbbVie Inc (US)
  • AstraZeneca Plc (UK)
  • Celgene Corporation (US)
  • Merck & Co., Inc. (US)
  • Celldex Therapeutics (US)
  • MacroGenics, Inc. (US)
  • Hoffmann-La Roche Ltd (Switzerland)
  • Merck KGaA (Germany)
  • Bristol-Myers Squibb Company (US)
  • Novartis AG (Switzerland)
  • Eli Lilly and Company (US)
  • Sanofi S.A (France) and few among others.

Avail Awesome Discount Offer

Market Analysis Global Breast Cancer Drug Market is rise gradually to an estimated value of USD 43.63 Billion by 2026 registering a CAGR of 11.1% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients.

Strategic Points Covered in TOC:
·Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Breast Cancer Drug market
·Chapter 2: Evaluating the leading manufacturers of the global Breast Cancer Drug market which consists of its revenue, sales, and price of the products
·Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales
·Chapter 4: Presenting global Breast Cancer Drug market by regions, market share and with revenue and sales for the projected period
·Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Get Detailed TOC

Segmentation: Global Breast Cancer Drug Market

By Mechanism of Cation Type

  • HER2 Inhibitors
  • Mitotic Inhibitors
  • Anti-metabolites
  • Aromatase Inhibitors
  • CDK 4/6 Inhibitors
  • Hormonal Receptor

By Type

  • Ductal Carcinoma In Situ (DCIS)
  • Invasive Ductal Carcinoma (IDC)
  • Tubular Carcinoma of the Breast
  • Medullary Carcinoma of the Breast
  • Mucinous Carcinoma of the Breast
  • Papillary Carcinoma of the Breast
  • Cribriform Carcinoma of the Breast
  • Invasive Lobular Carcinoma (ILC)
  • Inflammatory Breast Cancer
  • Lobular Carcinoma In Situ (LCIS)
  • Male Breast Cancer
  • Molecular Subtypes of Breast Cancer
  • Paget’s Disease of the Nipple
  • Phyllodes Tumors of the Breast
  • Metastatic Breast Cancer
  • Others

By Stage

  • T: Primary Tumor Size
  • N: Lymph Node Involvement
  • M: Cancer spread beyond the breast and lymph nodes

By Drug Type

  • Herceptin Hylecta
  • Atezolizumab
  • Talazoparib
  • Ribociclib
  • Abemaciclib
  • Neratinib
  • Palbociclib
  • Others

By Therapy Type

  • Medication
  • Chemotherapy
  • Targeted Therapy
  • Surgery

By Route of administration

  • Oral
  • Injectable

By End users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Market Segment by Regions, regional analysis covers:

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, UK, Russia and Italy)
  • Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
  • South America (Brazil, Argentina, Colombia)
  • Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Analysis Global breast cancer drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of breast cancer drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Speak to Author


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *